Dr. Odink is the President and Chief Development Officer of Thryv Therapeutics. Over the course of 30 years, she has been involved in pharmaceutical development across the spectrum of large and small molecules.

She started her career at Roche working in manufacturing process development and characterization of several of Roche's early-stage programs. After Roche, she began her career in start-up, venture backed biotech, first at Peninsula advancing a sterile filled antibiotic from pre-clinical to NDA which was acquired by Johnson and Johnson. At Anthera Pharmaceuticals, as the Chief of Technical Operations she advanced two products into phase 3, one a small molecule enzyme inhibitor targeting inflammation and the other a large molecule peptibody for lupus. At Eiger Biopharmaceuticals, she was SVP, Technical Operations advancing four of Eiger’s rare disease programs into the clinic, one of which was recently approved. At SiteOne Therapeutics, she served as Chief Development Officer and was instrumental in advancing a novel non-opioid pain therapeutic into the clinic. She obtained her Ph.D. in chemistry from University of California, Davis and B.S. in chemistry from California State University, Stanislaus.

• 

  President in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.

• 

  Chief Development Officer in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.